Orthoebolavirus zairense Inhibitors
1 drugsAbout Orthoebolavirus zairense
*Orthoebolavirus zairense*, or Zaire ebolavirus, is the most virulent of the ebolaviruses, responsible for most Ebola virus disease (EVD) outbreaks and fatalities. While viral entry and pathogenesis mechanisms are still being studied, targeting this virus is crucial for effective therapies against EVD. The virus itself is the direct causative agent of EVD.
As the direct cause of EVD, *Orthoebolavirus zairense* is a clear target for drug development, despite the lack of specific human genetic evidence. Therapies targeting the virus aim to disrupt its lifecycle and reduce its ability to cause disease. Further research is needed to identify vulnerabilities.
There is one FDA-approved drug, INMAZEB, an antibody developed by Regeneron, for treating *Orthoebolavirus zairense* infections. This single drug highlights the potential of targeting the virus to improve patient outcomes. Further antiviral strategies are needed.
Top Orthoebolavirus zairense Drugs
Regeneron is the only company with an approved drug for this target.
The market's low competition presents an opportunity for new entrants to develop alternative therapies.
Orthoebolavirus zairense Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Orthoebolavirus zairense, using antibody modality.
The lack of modality diversity suggests an opportunity for novel therapeutic approaches beyond antibodies.
Orthoebolavirus zairense Clinical Trials 2 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Orthoebolavirus zairense. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 | - |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Orthoebolavirus zairense Drug Approval Timeline (2020 - 2020)
INMAZEB was approved in 2020 and remains the most recent and only approved drug.
The stagnant approval timeline indicates a need for renewed investment and innovation in this therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Orthoebolavirus zairense. A trial counts if an approved drug acting on Orthoebolavirus zairense is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.